文献速递消化系统肿瘤

曲妥珠单抗美坦新对比紫杉类治疗经治HER2阳性局部晚期或转移性胃或胃食管结合部腺癌(GATSBY):一项国际随机开放标签适应性2/3期研究

Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study.
PubMed 文献 · Lancet Oncol · 2017-03-23

GATSBY研究在107个中心(28个国家)纳入经治HER2阳性晚期胃癌患者,随机接受曲妥珠单抗美坦新(2.4 mg/kg每周)或紫杉类。最终分析显示,曲妥珠单抗美坦新组中位总生存7.9个月 vs 紫杉类组8.6个月(HR 1.15,95%CI 0.87-1.51,单侧p=0.86),未优于紫杉类。

要点

  • 曲妥珠单抗美坦新组中位OS 7.9个月,紫杉类组8.6个月,HR 1.15(95%CI 0.87-1.51)。
  • 曲妥珠单抗美坦新组≥3级不良事件发生率60%,紫杉类组70%。
  • 经治HER2阳性晚期胃癌治疗选择仍有限,存在未满足需求。

核心结论

  • 曲妥珠单抗美坦新在经治HER2阳性晚期胃癌患者中未优于紫杉类。

研究设计与样本

  • GATSBY为国际随机开放标签适应性2/3期研究,在107个中心(28个国家)开展。
  • 1期阶段按2:2:1随机分配至曲妥珠单抗美坦新3.6 mg/kg每3周、2.4 mg/kg每周或紫杉类(多西他赛75 mg/m2每3周或紫杉醇80 mg/m2每周)。
  • 2期阶段按2:1随机分配至独立数据监查委员会选择的曲妥珠单抗美坦新2.4 mg/kg每周或紫杉类。
  • 随机化按世界区域、既往HER2靶向治疗和既往胃切除术分层,主要终点总生存在意向治疗人群中评估。

主要发现

  • 2012年9月3日至2013年10月14日,1期阶段70例接受曲妥珠单抗美坦新3.6 mg/kg每3周、75例接受2.4 mg/kg每周、37例接受紫杉类。
  • 截至2015年2月9日,2期阶段另有153例随机接受曲妥珠单抗美坦新2.4 mg/kg每周、80例接受紫杉类。
  • 曲妥珠单抗美坦新2.4 mg/kg每周组中位随访17.5个月(IQR 12.1-23.0),紫杉类组15.4个月(IQR 9.2-18.1)。
  • 曲妥珠单抗美坦新2.4 mg/kg每周组中位总生存7.9个月(95%CI 6.7-9.5),紫杉类组8.6个月(95%CI 7.1-11.2),HR 1.15(95%CI 0.87-1.51,单侧p=0.86)。
  • 曲妥珠单抗美坦新2.4 mg/kg组≥3级不良事件134/224例(60%),紫杉类组78/111例(70%)。

关键数值与推荐

  • 曲妥珠单抗美坦新2.4 mg/kg每周组导致死亡的不良事件8/224例(4%),紫杉类组4/111例(4%)。
  • 曲妥珠单抗美坦新2.4 mg/kg每周组严重不良事件65/224例(29%),紫杉类组31/111例(28%)。
  • 曲妥珠单抗美坦新2.4 mg/kg每周组导致治疗终止的不良事件31/224例(14%),紫杉类组15/111例(14%)。
  • 曲妥珠单抗美坦新2.4 mg/kg每周组最常见≥3级不良事件为贫血59例(26%)和血小板减少25例(11%),紫杉类组为中性粒细胞减少43例(39%)和贫血20例(18%)。

临床怎么用

  • 原文结论为曲妥珠单抗美坦新未优于紫杉类,经治HER2阳性晚期胃癌患者治疗选择仍有限。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although trastuzumab plus chemotherapy is the standard of care for first-line treatment of HER2-positive advanced gastric cancer, there is no established therapy in the second-line setting. In GATSBY, we examined the efficacy and tolerability of trastuzumab emtansine in patients previously treated for HER2-positive advanced gastric cancer (unresectable, locally advanced, or metastatic gastric cancer, including adenocarcinoma of the gastro-oesophageal junction). METHODS: This is the final analysis from GATSBY, a randomised, open-label, adaptive, phase 2/3 study, done at 107 centres (28 countries worldwide). Eligible patients had HER2-positive advanced gastric cancer and progressed during or after first-line therapy. In stage one of the trial, patients were randomly assigned to treatment groups (2:2:1) to receive intravenous trastuzumab emtansine (3·6 mg/kg every 3 weeks or 2·4 mg/kg weekly) or physician's choice of a taxane (intravenous docetaxel 75 mg/m2 every 3 weeks or intravenous paclitaxel 80 mg/m2 weekly). In stage two, patients were randomly assigned to treatment groups (2:1) to receive the independent data monitoring committee (IDMC)-selected dose of trastuzumab emtansine (2·4 mg/kg weekly) or a taxane (same regimen as above). We used permuted block randomisation, stratified by world region, previous HER2-targeted therapy, and previous gastrectomy. The primary endpoint (overall survival) was assessed in the intention-to-treat population. This study is registered with ClinicalTrials.gov, number NCT01641939. FINDINGS: Between Sept 3, 2012, and Oct 14, 2013, 70 patients were assigned to receive trastuzumab emtansine 3·6 mg/kg every 3 weeks, 75 to receive trastuzumab emtansine 2·4 mg/kg weekly, and 37 to receive a taxane in the stage 1 part of the trial. At the pre-planned interim analysis (Oct 14, 2013), the IDMC selected trastuzumab emtansine 2·4 mg/kg weekly as the dose to proceed to stage 2. By Feb 9, 2015, a further 153 patients had been randomly assigned to receive trastuzumab emtansine 2·4 mg/kg weekly and a further 80 to receive a taxane. At data cutoff, median follow-up was 17·5 months (IQR 12·1-23·0) for the trastuzumab emtansine 2·4 mg/kg weekly group and 15·4 months (9·2-18·1) in the taxane group. Median overall survival was 7·9 months (95% CI 6·7-9·5) with trastuzumab emtansine 2·4 mg/kg weekly and 8·6 months (7·1-11·2) with taxane treatment (hazard ratio 1·15, 95% CI 0·87-1·51, one-sided p=0·86). The trastuzumab emtansine 2·4 mg/kg group had lower incidences of grade 3 or more adverse events (134 [60%] of 224 patients treated with trastuzumab emtansine vs 78 [70%] of 111 patients treated with a taxane), and similar incidences of adverse events leading to death (eight [4%] vs four [4%]), serious adverse events (65 [29%] vs 31 [28%]), and adverse events leading to treatment discontinuation (31 [14%] vs 15 [14%]) than did taxane treatment. The most common grade 3 or more adverse events in the trastuzumab emtansine 2·4 mg/kg weekly group were anaemia (59 [26%]) and thrombocytopenia (25 [11%]) compared with neutropenia (43 [39%]), and anaemia (20 [18%]), in the taxane group. The most common serious adverse events were anaemia (eight [4%]), upper gastrointestinal haemorrhage (eight [4%]), pneumonia (seven [3%]), gastric haemorrhage (six [3%]), and gastrointestinal haemorrhage (five [2%]) in the trastuzumab emtansine 2·4 mg/kg weekly group compared with pneumonia (four [4%]), febrile neutropenia (four [4%]), anaemia (three [3%]), and neutropenia (three [3%]) in the taxane group. INTERPRETATION: Trastuzumab emtansine was not superior to taxane in patients with previously treated, HER2-positive advanced gastric cancer. There is still an unmet need in this patient group and therapeutic options remain limited. FUNDING: F Hoffmann-La Roche.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Thuss-Patience PC, Shah MA, Ohtsu A, et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncol. 2017. PMID: 28343975. doi:10.1016/S1470-2045(17)30111-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。